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Available online 30 April 2016Successful stem cell therapy after acute myocardial infarction (AMI) is hindered by lack of engraftment of sufﬁ-
cient stem cells at the site of injury.Wedesigned a novel technique to overcome this problemby assembling stem
cell-microbubble complexes, named ‘StemBells’.
StemBellswere assembled through binding of dual-targetedmicrobubbles (~3 μm) to adipose-derived stem cells
(ASCs) via a CD90 antibody. StemBells were targeted to the infarct area via an ICAM-1 antibody on the
microbubbles. StemBells were characterized microscopically and by ﬂow cytometry. The effect of ultrasound
on directing StemBells towards the vessel wall was demonstrated in an in vitro ﬂow model. In a rat AMI-
reperfusion model, StemBells or ASCs were injected one week post-infarction. A pilot study demonstrated feasi-
bility of intravenous StemBell injection, resulting in localization in ICAM-1-positive infarct area three hours post-
injection. In a functional study ﬁveweeks after injection of StemBells cardiac functionwas signiﬁcantly improved
compared with controls, as monitored by 2D-echocardiography. This functional improvement neither coincided
with a reduction in infarct size as determined by histochemical analysis, nor with a change in anti- and pro-
inﬂammatory macrophages.
In conclusion, the StemBell technique is a novel and feasible method, able to improve cardiac function post-AMI
in rats.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Adult mesenchymal stem cell therapy has been proposed as a prom-
ising therapy for regenerative tissue repair, for example to prevent heart
failure development after acute myocardial infarction (AMI) (Shah and
Shalia, 2011; Wollert et al., 2004). However, one of the major problems
of stemcell therapy is a lack of engraftment of sufﬁcient stemcells at the
site of injury (van Dijk et al., 2011; Berardi et al., 2011). Wer, Department of Cardiology, De
herlands.
ans).
. This is an open access article underhypothesized that when retention and engraftment of stem cells are in-
creased, the therapeutic effect of stem cells will improve. Therefore, we
designed a novel targeting technique to direct adipose-derived stromal/
stem cells (ASCs) speciﬁcally to the activated endothelium of blood ves-
sels within the infarct area in the heart by coating them with dual-
targeted microbubbles.
We used ASCs, because adipose tissue is a rich source of mesenchy-
mal stem cells, which can be harvested easily, show high proliferation
rates in culture and have the capacity to differentiate into several cell
types amongst which cardiomyocytes (Oedayrajsingh-Varma et al.,
2006; van Dijk et al., 2008; Carvalho et al., 2013; Rangappa et al.,
2003). Furthermore, it has been shown that ASCs have a beneﬁcial effect
on cardiac function post-AMI in several pre-clinical studies (van Dijk
et al., 2011; Berardi et al., 2011; Yamada et al., 2006). Early clinical trialsthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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provement for ASC therapy (Houtgraaf et al., 2012; Janssens et al., 2006;
Jeevanantham et al., 2012; Assmus et al., 2014).
To be able to direct the ASCs to the infarct area we employed the so-
called microbubbles, which are small (2–4 μm) gas-ﬁlled bubbles origi-
nally developed as contrast agents for echocardiography (Dijkmans
et al., 2004). Nowadays, microbubbles can also be designed as targeting
agents by conjugating antibodies, ligands or peptides to the
microbubble shell (Klibanov et al., 2004; Kokhuis et al., 2013). We
have constructed stem cell-microbubble complexes, named
‘StemBells’, by coating ASCs with microbubbles using a CD90 an-
tibody via biotin-streptavidin bridging (Fig. 1A). Additionally,
an antibody against ICAM-1, an adhesion molecule expressed on
activated endothelium of blood vessels within the infarct area
(Benson et al., 2007), was simultaneously conjugated to the
microbubble shell to create a bridge and improve the attachment
of the StemBells speciﬁcally in the infarct area. Application of the
microbubbles has several beneﬁts. First, it allows coupling of a
targeting antibody to the ASCs without modifying the stem cell it-
self. Second, the microbubbles cause buoyancy and susceptibility
of the ASCs to the acoustic radiation force exerted by diagnostic
ultrasound, as we previously showed in an chicken embryo
using intravital microscopy (Kokhuis et al., 2014). StemBells can
thus be pushed from the center of the blood stream to the vessel
wall by ultrasound, further enhancing the effect of targeting.
Here, we describe the development and validation of this novel
StemBell technique.We demonstrate its safety, as well as its positive ef-
fect on cardiac function in a rat AMI study.Fig. 1. StemBells A) Schematic drawing of a StemBell: a stem cell-microbubble complex coup
presence of two antibodies on one microbubble. Upper left panel: bright ﬁeld image; upper rig
is an overlay. C) Microscopic bright ﬁeld images showing three planes of a 3D stack of a Stem
ultrasound. Data is shown as mean ± SEM (n= 6).2. Methods
2.1. Isolation and culture of the stromal vascular fraction from human and
rat adipose tissue
For isolation of the human stromal vascular fraction (SVF), subcuta-
neous abdominal adipose tissue samples were obtained as waste mate-
rial after elective surgery and donated upon informed consent of the
patients from three clinics in the Netherlands (Tergooi Ziekenuis, Hil-
versum; ‘Jan van Goyen’ clinic, Amsterdam; VU UniversityMedical Cen-
ter, Amsterdam). This study complied with the principles of the
Declaration of Helsinki. SVF was isolated as described previously
(Oedayrajsingh-Varma et al., 2006). Adipose tissue was stored in sterile
phosphate-buffered saline (PBS; Braun, Melsungen, AG, USA) at 4 °C
and processed within 24 h after surgery as described previously
(Oedayrajsingh-Varma et al., 2006). In brief, adipose tissue was enzy-
matically digested using 0.1% collagenase A (Roche Diagnostics GmbH,
Mannheim, Germany) in PBS containing 1% bovine serum albumin
(BSA; Roche Diagnostics) for 45 min at 37 °C under intermittent shak-
ing. To remove contaminating erythrocytes, the cells were subjected
to Ficoll density centrifugation (Lymphoprep, ρ01.077 g/ml, osmolarity
280 ± 15 mOsm; Axis-Shield, Oslo, Norway).
For rat SVF isolation, adipose tissue from the inguinal fat pad of 30
male Wistar rats (Harlan Laboratories, Horst, the Netherlands; 300–
400 g) was resected, pooled per 5 rats, collected in sterile PBS and proc-
essed immediately after resection as described previously (van Dijk
et al., 2011). Animals were treated according to national guidelines
and with permission of the Institutional Animal Care and local Animalled via streptavidin-biotin-antibody bridging. B) Microscopic images demonstrating the
ht panel: anti-CD90 in red; lower left panel: anti-ICAM-1 in green, and lower right panel
Bell. D) Quantiﬁcation of the number of microbubbles per stem cell includes the effect of
8 L. Woudstra et al. / Stem Cell Research 17 (2016) 6–15Ethical Committee of the VU University Medical Center (Amsterdam,
theNetherlands), which conformswith theNational Institutes of Health
Guide for the Care and Use of Laboratory Animals (NIH Pub. No. 85-23,
Revised 1996).
Both human and rat SVF cells were seeded at 1 × 105 cells/cm2 in
Dulbecco's modiﬁed Eagle's medium (DMEM; BioWhittaker, Cambrex,
Verviers, Belgium) containing 100 U/ml penicillin, 100 μg/ml strepto-
mycin, and 2 mM L-glutamine (all from Gibco, Invitrogen, Carlsbad,
CA, USA). Culture medium for rat SVF cells was supplemented with
10% fetal bovine serum (FBS; HyClone, South Logan, UT, USA). For
human SVF cells, culture medium was supplemented with 5% human
platelet lysate and 10 IU/ml heparin (Leo Pharma, Amsterdam, the
Netherlands) (Naaijkens et al., 2012). Cells were cultured in a humidi-
ﬁed atmosphere of 5% CO2 at 37 °C. Media were changed twice a week.
The percentage of ASCs within the SVF was determined by a colony
forming unit assay. SVF cells were seeded in 6-well culture dishes
(Greiner Bio one, USA) at a density of 10 and 100 cells/cm2 (in triplicate)
in ASC growthmediumwhich consisted of low glucose Dulbecco'smod-
iﬁed Eagle's medium (DMEM). After 14 days, cells were washed with
PBS, ﬁxed with 4% formalin for 10 min, and subsequently stained in a
1% toluidine blue solution in borax buffer for 1 min and washed twice
with H2O. Colonies containing at least 50 cells were scored using a Ste-
reomicroscope (Zeiss, Germany).
Prior to in vitro experiments or in vivo injection SVF from liquid ni-
trogen storage was thawed and seeded at 1 × 105 cell/cm2 in ASC
growth medium. When ASCs reached 90% conﬂuency, cells were de-
tached with 0.5 mM EDTA/0.05% trypsin (Gibco). Cell size was deter-
mined using a Scepter handheld automatic cell counter (Millipore,
Billerica, MA, USA). For in vitro experiments ASCs in passage 1 or 2
were used, for in vivo experiments ASCswere used in passage 1, and cul-
tured for six days.
2.2. StemBell assembly
Biotinylated microbubbles with a perﬂuorobutane (C4F10) gas core
were made by soniﬁcation, as described by Klibanov (Klibanov et al.,
2004). The shell was composed of 1,2-distearoyl-sn-glycerol-3-
phosphocholine (DSPC; 59.4 mol%; Sigma-Aldrich, the Netherlands);
polyethylene glycol (PEG)-40 stearate (35.7 mol%; Sigma-Aldrich);
1,2-distearoyl-sn-glycerol-3-phosphoethanolamine (DSPE)-PEG(2000)
(4.1 mol%; Avanti Polar Lipids) and DSPE-PEG(2000)-biotin (0.8 mol%;
Avanti Polar Lipids). Microbubbles (109 per ml) had an average diame-
ter of 3.5 μmandwere stored in sealed glass vials with a C4F10 gas head-
space to prevent deﬂation. To make dual-targeted microbubbles, 100 μl
biotinylatedmicrobubbleswerewashed twicewith PBS/C4F10 by centri-
fugation (400g, 1 min, 4 °C) to remove superﬂuous biotin and resolved
in PBS/C4F10. Next, streptavidin (1 mg/ml; Sigma) was added and the
mixture was incubated at 4 °C for 25 min. Microbubbles were again
washed to remove superﬂuous streptavidin and resolved in PBS/C4F10.
Next, biotinylated mouse-anti-rat-CD90 (1 μg; BD Bioscience) and bio-
tinylated mouse-anti-rat-ICAM-1 (1 μg; ACRIS) were added and the
mixture was incubated at 4 °C for 25 min. These dual-targeted
microbubbles were again washed and resolved in DMEM. Final concen-
tration of themicrobubbleswas determined using aMultisizer 3 Coulter
Counter (Beckman Coulter, Fullerton, CA, USA). The presence of both
antibodies was veriﬁed using a Cy3-labeled anti-IgG1-mouse
(Invitrogen) and a FITC-labeled anti-IgG2a-mouse (Invitrogen) by ﬂuo-
rescence microscopy (Marianas, I.I.I., Denver, CO, USA) with a 40× ob-
jective (Zeiss, Germany).
Prior to incubation with the dual-targeted microbubbles, ASCs were
labeled with Hoechst 33342 (10 μg/ml; Invitrogen) at 37 °C for 30 min.
In vitro testing demonstrated that this concentration provided adequate
labelingup to 42 days, as determined byﬂuorescencemicroscopy. In ad-
dition, this concentration had no effect on cell viability, determined by
the addition of propidium iodide (PI) to the cells and counting of PI-
positive, i.e. dead cells. Hoechst labeling also had no effect on cellproliferation as determined by cell proliferation assay (data not
shown). Hoechst-labeled ASCs were then incubated with dual-
targeted microbubbles in a 100:1 ratio under continuous rotation at
room temperature for 25min. Aminimumof 10 StemBells per prepara-
tion was analyzed for the number of microbubbles per StemBell, using
differential interference contrastmicroscopy (Marianas)with a 40× ob-
jective providing 3D-images of a StemBell.
2.3. Ultrasound application protocol
Ultrasoundwas applied using a 1-MHzunfocused transducer (V303-
SU, Panametrics Inc, Waltham, MA, USA) or a 500 kHz PZT transducer
(V318, Panametrics Inc) coupled to an arbitrary waveform generator
(33220A, Agilent, Palto Alto, CA, USA) and a linear 60-dB power ampli-
ﬁer (150A100B, Ampliﬁer Research, Bothell, WA, USA). The ultrasound
signal was monitored by a synchronized digital oscilloscope (GOULD
DSO 465, Valley View, OH, USA). Peak negative acoustic pressure was
100 kPa as veriﬁed with a calibrated hydrophone (PA076; Precision
Acoustics, Dorchester, UK). ASCs or StemBells in suspension were ex-
posed to sine-wave ultrasound bursts with a 10% duty cycle and 1 kHz
pulse repetition frequency for one minute. Rats were exposed to the
same ultrasound protocol by positioning the transducer parasternal at
the anterior wall and location of the infarct area.
2.4. Cell viability assay
Cell viability was analyzed by ﬂow cytometry using an Annexin-V-
FITC and Propidium Iodide (PI) Apoptosis Detection Kit (eBioscience,
San Diego, USA), as described by the manufacturer, to test whether
the assembly of StemBells, as well as the application of ultrasound af-
fected cell viability. In short, following StemBell formationwith orwith-
out ultrasound treatment, cellswere labeledwith Annexin-V in the dark
for 30min. Prior to analysis, PI was added for at least 30 s. Fluorescence
of both Annexin-V and PI was measured with a FACS Calibur ﬂow
cytometer (BD Biosciences). Stem cells negative for both Annexin-V
and PIwere scored as viable. Datawas analyzedwith CellQuest-Pro soft-
ware (BD Biosciences).
2.5. Attachment assay
To investigate the ability to attach to a surface despite the numerous
microbubbles bound to the cell surface 48 × 103 StemBells with and
without exposure to ultrasound were seeded in a culture dish. After
seeding, cells were allowed to attach in a humidiﬁed incubator for 5,
10, or 20 min, followed by removing unattached cells by washing with
PBS. The number of attached cells was quantiﬁed using CyQuant Cell
Proliferation Kit (Invitrogen) according to the manufacturer's protocol.
2.6. In vitro ﬂow system to assess acoustic radiation force
AVI-slideﬂow chamber (Ibidi, Martinsried, Germany)wasmounted
on theMarianasmicroscope allowing real-time visualization of acoustic
radiation force acting on ﬂowing StemBells. Shear stress on the
StemBells (1 × 106 cells/50ml) was 0.2 dyn/cm2. Sequel bright ﬁeld im-
ages were made at 20 Hz. After 2 s the ultrasound was switched on for
the total duration of the image capture, i.e. 20 s.
2.7. Rat model of acute myocardial infarction
An acute myocardial infarction was induced as described previously
(van Dijk et al., 2011; van Dijk et al., 2009) in eight-week old male
Wistar rats (300–400 g, Harlan, the Netherlands) that were housed
under constant temperature (21–22 °C), humidity (60–65%) and
light–dark periodicity (L:D 12:12). Experimental procedures started
after twoweeks of acclimatization. Rats were anesthetized using subcu-
taneous hypnorm/dormicum (fentanyl and ﬂuanisone 0.5 ml/kg,
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10–0.4 mbar (Zoovent ventilator, Netherlands). Heart rate was moni-
tored using Einthoven I ECG. A left thoracotomy in the fourth intercostal
space was made, and the left anterior descending coronary artery was
ligated using a 6.0 prolene suture (Ethicon, Germany). Ischemia was
maintained for 40 min, followed by reperfusion and chest closure. This
procedure results in relatively small non-aneurysmatic infarcts, compa-
rable to what occurs in the majority of patients suffering from AMI
(Pfeffer et al., 1979). StemBells or ASCs (both 1 × 106/600 μl DMEM)
or vehicle (an equal volume of DMEM alone) were injected intrave-
nously (i.v.) in the tail vein one week post-AMI under isoﬂurane (3%)
anesthesia. Directly prior to injection the suspension was vigorously re-
suspended to prevent clustering of the ASCs or StemBells.
A pilot short-term experiment was carried out in ﬁve rats to test
whether ICAM-1 targeted StemBells (~20 μm∅) injected intravenously
were able to bind in the infarcted myocardium and whether they co-
localized with ICAM-1 positivity in the infarct area three hours post-
injection.
In the long-term functional experiment 27 rats were anesthetized
one week post-AMI and injected with either ASCs (n = 11), StB (n =
9) or Vehicle (n = 7), followed by ultrasound exposure. Animals were
sacriﬁced ﬁve weeks post-injection and putative effects on stem cell re-
trieval and differentiation, cardiac function, infarct size andmacrophage
inﬁltration were analyzed. For analysis of cardiac function, 2D-
echocardiograpy was performed prior to AMI (baseline), prior to injec-
tion (day 7) and prior to sacriﬁce (day 42), using a 13 MHz linear-array
transducer (ProSound SSD-4000 PureHD, Aloka, Tokyo, Japan). Short-
axis images were analyzed to determine wall thickness and lumen di-
ameter of the left ventricle, in order to calculate fractional shortening
(FS), wall thickness and stroke volume (SV). After sacriﬁce hearts
were isolated and cut into ﬁve equal slices of approximately 2.5 mm
thickness. The middle two slices were snap frozen in liquid nitrogen,
the apex and the top two slices (as seen from the base of the heart)
were embedded in parafﬁn.
2.8. Fluorescence microscopy
The number of ﬂuorescent stem cells in frozen heart slides was de-
termined as previously described by van Dijk et al. (2011), with a
minor adaptation that we now used the nuclear stain Hoechst in order
to retrace engrafted stem cells. To retrieve Hoechst-positive stem cells
and determine putative co-localization with ICAM-1 in the pilot study,
four frozen heart slides per ratwere stainedwithmonoclonal antibodies
against goat-anti-ICAM-1 (1:100, Abcam, Cambridge, UK) and mouse-
anti-α-actinin (1:200, 4 °C overnight, Sigma), followed by incubation
with a rabbit-anti-goat-FITC and a donkey-anti-mouse Cy5 secondary
antibody (both 1:100, BD) for 30 min in the dark.
In the functional study Hoechst-positive cells were also checked for
putative differentiation towards cardiomyocytes. For this, four frozen
heart slides per rat were counterstained with mouse monoclonal anti-
bodies against troponin T (1:25, 4 °C, overnight; AbD Serotec, UK) or
connexin 43 (1:1000, 4 °C, overnight; Abcam), both followed by incuba-
tion with a goat-anti-mouse-FITC secondary antibody (1:100, BD).
Fluorescencemicroscopy (Marianas I.I.I.) was performedwith a 10×
and a 40× objective (Zeiss). Fluorescent images were analyzed using
SlideBook software (I.I.I.). Due to the Hoechst labeling of the ASCs no
nuclear counterstain could be used for thewhole heart tissue. However,
the tissue morphology was clear from both autoﬂuorescence as well as
from the cardiomyocyte counterstains. The lung and liver were also
screened.
2.9. Histological staining to determine infarct size
To determine the infarct size a phosphotungstic acid hematoxylin
(PTAH) staining was performed as described previously (van Dijk
et al., 2009), on four heart slides per rat distal from the suture: twofrozen and two parafﬁn embedded heart slides. Parafﬁn embedded
slides were deparafﬁnized and dehydrated, whereas frozen slides
were ﬁxed for 10 min in 100% acetone. After washing with PBS, the
slides were incubated in Bouin at 60 °C for 30 min. After a cooling
down period of 15 min and a wash step in water of 10 min, slides
were incubated in PTAH at 60 °C for 60 min. After cooling down, slides
were dehydrated, washed in xylene and covered. PTAH stains viable
cardiomyocytes purple and infarcted cardiomyocytes pink, allowing in-
farct area measurements on scanned slide (Pannoramic Desk scanner
and Pannoramic Viewer 1.15.3 software 3DHistech, Budapest,
Hungary). Infarct size was expressed as the percentage of the surface
area per whole heart slide, averaged for four cross sections.
2.10. Immunohistochemical staining of macrophages
To determine the inﬂammatory healing process post-AMI, the num-
ber and subtype of macrophages were determined by immunohisto-
chemistry on serial parafﬁn slides. For total numbers of macrophages
a mouse-anti-rat CD68 antibody (1:100, RT, 60 min; Serotec) was
used after antigen retrieval with 0.1% pepsin (in 0.02 M HCl, 37 °C,
30 min). For the late, pro-healing M2 subtype of macrophages a
mouse-anti-rat ED2 antibody (1:200, RT, 60 min; a gift from prof. C.D.
Dijkstra, VUmc, Amsterdam, the Netherlands) was used after antigen
retrieval with 10 mM sodium citrate buffer, pH 6.0, by boiling the slides
in this buffer for 10 min. A secondary antibody Envision-HRP (1:200,
30 min, DakoCytomation, USA) was used. Staining was visualized
using Envision-diaminobenzidin (DakoCytomation). Control slides in-
cubated with PBS instead of primary antibody yielded no staining (not
shown). CD68 and ED2 positive cells in the infarct area were scoredmi-
croscopically using a 20× objective (Zeiss, Germany). Infarct area was
measured using Pannoramic Viewer.
2.11. Statistical analysis
All in vitro experiments were performed at least six times. For all
in vivo data non-parametric Mann–Whitney or Kruskal–Wallis rank
sum test was used, followed by Dunn's multiple comparison (GraphPad
Prism6.0). The echocardiographic data at baseline and at day 7were an-
alyzed for equal variances, and were subsequently taken together to
provide a single value for all measurements at baseline and day 7.
These values are displayed in the graphs as dotted lines. A p-value
smaller than 0.05 was considered to represent a statistically signiﬁcant
difference. Data is described as mean ± standard error of the mean
(SEM).
3. Results
3.1. In vitro characterization of StemBells
Rat SVF cells were isolated from inguinal fat. The percentage of colo-
ny forming cells indicative of the percentage of stem cells in the stromal
vascular fractionwas 11.1±1.8%. After a culture period of six days, ASCs
were characterized and showed stem cell morphology with an average
cell size of 14.3 ± 0.3 μm (not shown) in accordance with our previous
studies (van Dijk et al., 2011; Naaijkens et al., 2012). Dual-targeted
microbubbles were successfully assembled showing the presence of
both anti-CD90 and anti-ICAM-1 antibodies on the microbubble shell
(Fig. 1B). Next, these dual-targeted microbubbles were added to rat
ASCs in a 100:1 ratio to form stem cell-microbubble complexes,
named “StemBells” (Fig. 1C). ASCs were coated with an average of
32.5 ± 4.2 microbubbles/cell (Fig. 1D). This number was not affected
by ultrasound exposure (30.6 ± 3.7 microbubbles/cell).
The procedure to assemble StemBells, using rat ASCs, did not signif-
icantly affect cell viability (ASCs 85.7±2.3% viable cells; StB 87.1±1.4%
viable cells). Although exposure to ultrasound slightly, but non-
signiﬁcantly decreased cell viability (StB + US 80.0 ± 2.3% viable
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out exposure to ultrasoundwere similarly capable of attachment to cul-
ture plastic (Fig. 2B), with already 60% attachment after 5 min,
increasing up to 95% at 20 min. Next, it was studied, using human
ASCs, whether StemBells with dual-targeting microbubbles were sus-
ceptible to acoustic radiation force in an in vitro ﬂow assay. Ultrasound
displaced StemBells to the side of the ﬂow channel in the direction of
the ultrasonic wave propagation and perpendicular to the direction of
ﬂow with a translation speed of 23.2 mm/s orthogonal to the ﬂow
(Fig. 2C). ASCs alone were not susceptible to ultrasound (not shown).
To summarize, StemBells were successfully assembled, susceptible
to acoustic radiation force, without affecting the number of
microbubbles per StemBell, and without affecting cell viability and at-
tachment rate. These in vitro results made application of the StemBell
technique suitable for ﬁrst in vivo usage.
3.2. Intravenously delivered StemBells target to the infarcted myocardium
In a pilot study StemBells were injected intravenously in ﬁve rats
7 days after AMI. No shortness of breath was observed and no rats
died as a consequence of injecting StemBells. Using ﬂuorescence mi-
croscopy on frozen heart slides to retrieve Hoechst-positive cells it
was shown that the StemBells were able to extravasate and bind to
the myocardium, speciﬁcally in the infarct area (8.4 ± 3.3 cells/mm2),
co-localizing with ICAM-1 (Fig. 3A). Virtually no cells were found in
the non-infarct areas (0.1 ± 0.02 cell/mm2; Fig. 3B).
3.3. StemBells have long term beneﬁcial effects on heart function after AMI
Following the pilot study, we determined in a long term functional
studywhether injection of StemBells 7 days after AMI improved cardiac
function at 42 days post-AMI. To determine putative effects on cardiac
function 2D-echocardiographywasperformed prior to AMI, immediate-
ly prior to stem cell injection and immediately prior to sacriﬁce at day
42 post-AMI. Analysis of the fractional shortening (FS), a measurement
reﬂecting left ventricular contractile capacity showed that contractilityFig. 2. In vitro functionality A) Quantiﬁcation of stem cell viability using ﬂow cytometry with
ultrasound (US) at 5, 10 and 20 min after seeding to tissue culture plastic. Data is shown a
susceptibly of a StemBell in a ﬂow system. Direction of ﬂow is from bottom to top. Ultrasou
displacing with a translational speed of 23.2 mm/s orthogonal to the ﬂow.declined from50.3±1.2% at baseline to 34.3±1.7% on day 7 (both rep-
resented by dotted lines, Fig. 4A). The vehicle group displayed a further
decline to 27.0 ± 1.8% on day 42. The ASC group showed minor im-
provement (36.5 ± 3.1% on day 42), and only the StB group showed a
signiﬁcant improvement in FS (40.5 ± 3.8% on day 42; p b 0.01) com-
paredwith the vehicle group. Stroke volumeanalysis showed similar re-
sults (Fig. 4B), with a signiﬁcant improvement of stroke volume in the
StB group (0.44 ± 0.03 ml) as compared with the vehicle group
(0.32 ± 0.02 ml; p b 0.01), and compared with baseline (0.32 ± 0.01
ml; p b 0.05). Subsequently, the left ventricle wall thickness of the
non-infarcted posterior wall was determined to study putative post-
AMI hypertrophy (Fig. 4C). No changes in wall thickness were observed
on day 7 (0.18 ± 0.01 cm) compared with baseline (0.19 ± 0.01 cm;
p = 0.99). However, in the vehicle group signiﬁcant thickening of the
posterior wall was found on day 42 (0.24 ± 0.02 cm; p b 0.01 vs. both
baseline and day 7), indicative for cardiac remodeling towards hyper-
trophy. This thickening was also present, but to a lesser degree in the
ASC group (0.22 ± 0.01 cm on day 42; p b 0.01 vs. baseline and day
7). Notable, the posterior wall in the StB group did not show any chang-
es on day 42 compared with baseline and day 7 (0.19± 0.01 cm on day
42; p = 0.99), and was signiﬁcantly different from both the vehicle
(p b 0.05) and ASC group (p b 0.05). No changes were observed in the
anterior wall where the infarction was induced (data not shown).
Thirty-ﬁve days after injection Hoechst-positive cells were still visi-
ble and were predominantly found as solitary cells speciﬁcally within
the infarct area (Fig. 5A). These labeled stem cells were not found in
the lungs or liver. A small, non-signiﬁcant increase in the number of
stem cells was found in the infarct area of StB-treated rats (4.6 ± 1.1
cells/mm2) compared with ASC-treated rats (3.3 ± 1.0 cells/mm2,
p = 0.29), as shown in Fig. 5B. Hardly any cells were found in the
non-infarct area (ASCs 0.03 ± 0.01; StB 0.13 ± 0.08 cells/mm2). All re-
trieved stem cells showed expression of the cardiomyocyte markers
(Naaijkens et al., 2012) Connexin 43 (Fig. 5C, left panel) and Troponin
T (Fig. 5C, right panel), with no difference between the ASC and StB
group. Albeit that intensity levels of these markers were markedly
lower in the retrieved stem cells than in healthy cardiomyocytes.Annexin V and propidium iodide (PI). B) Attachment rate of StemBells with or without
s mean ± SEM (n = 3). C) Sequential microscopic bright ﬁeld images demonstrating
nd exerts acoustic radiation force from right to left. Arrow indicates a StemBell in focus
Fig. 3. In vivo pilot study A) Fluorescence microscopy image showing a Hoechst-positive stem cell (blue) within ICAM-1 positive region (red) next to cardiomyocytes (green).
B) Quantiﬁcation of the number of Hoechst-positive StemBells in non-infarct area and infarct area. Data is shown as mean ± SEM (n = 5).
11L. Woudstra et al. / Stem Cell Research 17 (2016) 6–15Next, infarct sizes were determined by a PTAH staining on the heart
slides (van Dijk et al., 2011; van Dijk et al., 2009). A small infarct size of
5.9 ± 0.8% was found in the vehicle-treated animals, 5.7 ± 1.2% in ASC-
treated animals and 8.0 ± 1.6% in StB-treated animals, with no signiﬁ-
cant differences between the groups (Fig. 6A; p = 0.40).
Finally, the number and subtype of macrophages within the infarct
area were quantiﬁed to determine a putative effect of the stem cells
on the healing process post-AMI. However, also here no differences
were found in the total number of macrophages (CD68 positive) per
mm2 (Fig. 6B), or the number of pro-healing ED2 positive macrophages
(Fig. 6C), nor in the ratio of ED2/CD68 (Fig. 6D).4. Discussion
In this study we described the development of a novel technique to
target stem cells speciﬁcally to the infarct area by the assembly of stem
cell-microbubble complexes, named StemBells. These StemBells were
ﬁrst in vitro characterized, showing high viability after assembly and ul-
trasound exposure, as well as susceptibility to acoustic radiation force.
In vivo this new stem cell delivery technique proved to be safe for intra-
venous injectionwith StemBells reaching the infarct area of the heart. In
addition, StemBells signiﬁcantly improved cardiac function,independent of an effect on infarct size or inﬂammatory macrophages
ﬁve weeks after injection.
We developed our novel targeting technique in order to overcome
one of the major problems with stem cell therapy, namely the high
wash-out of injected stem cells by the blood and low engraftment
rate. This high-washout of over 90% by the blood is irrespectively of
the delivery route of the stem cells (Hale et al., 2008; Hou et al., 2005;
Perin et al., 2008; Baklanov et al., 2006). In the pilot short-term study
the retrieved cells co-localized with ICAM-1 positive infarct area three
hours after StemBell injection. This demonstrated safe passage of the
StemBells through the pulmonary microcirculation and extravasation
within the infarct area, without any complications such as shortness of
breath or suffocation. Although intravenous delivery has been put
away as non-effective due to pulmonary ﬁrst-pass effect, recent animal
studies demonstrated that stem cells do safely traverse the pulmonary
circulation in mice (Geng et al., 2014), rats (Zanetti et al., 2015) and
pigs (Makela et al., 2015). In addition, we previously demonstrated
that culturing ASCs for several passages does result in obstruction in
the lungs (van Dijk et al., 2011), indicating that culturing changes the
stem cells in such a way that they are entrapped in the lungs. Whereas
coupling microbubbles to ASCs which were cultured for only one pas-
sage did not lead to entrapment in the lungs. Naturally, smaller cells
or cell-constructs traverse the pulmonary circulation easier and faster
Fig. 4. In vivo functional data Analysis of echocardiography short-axis images for
A) fractional shortening (%) on day 42, with dotted lines representing baseline (day
0) and day 7 post-AMI. B) Stroke volume (ml). C) Posterior wall thickness (cm). Data is
shown as mean ± SEM (n = 7 for Vehicle, n = 11 for ASCs, n = 9 for StB).
Fig. 5. In vivo stem cell retrieval A) Fluorescencemicroscopy image of Connexin 43 (green)
stained heart slide. Arrows indicate presence of Hoechst-positive stem cells (blue) within
the infarct area. B) Quantiﬁcation of the number of stem cells per mm2. C) Retrieved stem
cells at day 42 stained positive for cardiomyocyte speciﬁc markers Connexin 43 (left
panel) and Troponin-T (right panel). Data is shown as mean ± SEM (n = 3).
12 L. Woudstra et al. / Stem Cell Research 17 (2016) 6–15than larger particles and cells (Zanetti et al., 2015). With future clinical
application in mind, we deliberately chose for intravenous delivery. For
the patient a minimally invasive, intravenous drop with a StemBell sus-
pension at the out-patient clinic is more attractive than an additional
catheterization for intracardiac delivery, fromboth patient and econom-
ical view. The patient could even receive multiple treatments of
StemBells in combination with ultrasound exposure, something that
one would not readily do for intracardiac delivery.
Previously it was described that bi-directional antibodies against
myosin light chain in mice (Lee et al., 2007) or VCAM in rats (Lum
et al., 2004) that were used to increase homing of hematopoietic stem
cells to the heart. The results from our pilot study now demonstratedthat our ICAM-1 targeted StemBells had the same effect as the retrieved
stem cells co-localized with ICAM-1 upregulated in the infarct area.
Even more, StemBells— in addition to their targetingmoiety— are sus-
ceptible to ultrasound. This was demonstrated by the ability of ultra-
sound to displace StemBells over a relevant distance in vitro in this
study, as well as previously in a vitelline vein of a chick embryo
(Kokhuis et al., 2014), locally aiding the StemBells to slow down in the
bloodstream and enhance contact to the vessel wall. The application of
microbubbles in the aid of improving stem cell delivery over the endo-
thelium has been studied before (Ghanem et al., 2009; Toma et al.,
2011). In the study performed by Ghanem et al. (2009) ultrasound-
mediatedmicrobubble destructionwas applied in rats four days post is-
chemia–reperfusion, and 15 min prior to intra-aortic bone-marrow
mesenchymal stem cell (BM-MSC) injection. One hour after injection
it was shown that destruction of microbubbles, focused at the infarct
site, resulted in signiﬁcantly enhanced regional adhesion and
Fig. 6. In vivo analysis on the long term. A) Quantiﬁcation of PTAH staining of heart slides showing infarct size. B) Quantiﬁcation of the number of macrophages: Total number of CD68
positive cells per mm2. C) Number of ED2 positive, type 2 macrophages per mm2. D) ED2 positive cells expressed as percentage of total number of macrophages. Data is shown as
mean ± SEM.
13L. Woudstra et al. / Stem Cell Research 17 (2016) 6–15transendothelial migration BM-MSCs: 14.6 cells/heart slide vs. 9.5 cells/
heart slide in animals not pretreated with US and microbubbles
(Ghanem et al., 2009). The other study, performed by Toma et al.
(2011), showed that non-targeted microbubbles in combination with
ultrasound were able to direct BM-MSC to mechanically injured endo-
thelium of a rabbit aorta in vivo, resulting in 3.3 cells/mm2 at the
ultrasound-exposed segments of the aorta (Toma et al., 2011). Although
different experimental models, the number of stem cells we retrieved
was in the same order of magnitude: 8.4 cells/mm2 (13.4 cells/heart
slide) in the infarct area three hours after injection.
Following the safety pilot study, a long term functional study was
performedwhere treatment of the rats with StemBells signiﬁcantly im-
proved their cardiac function as demonstrated by echocardiography. A
functional improvement was found in a signiﬁcantly better fractional
shortening in the StemBell group, concordantly, the StemBell group
had the highest stroke volume. Finally in the StemBell group thickening
of the non-infarcted posterior left ventricle wall was prevented. These
functional effects could not be explained by a difference in infarct size
between the groups. In the literature several studies have shown im-
proved cardiac function without an effect on infarct size, e.g. in rats
where ASCs were injected 24 h (Danoviz et al., 2010) or
1 week(Rasmussen et al., 2014) post-infarction in a model with a per-
manent ligation, as well as in pigs where ASCs were injected 1 week
post-infarction induced by a balloon angioplasty for 3 h followed by re-
perfusion (Valina et al., 2007). Besides studying infarct size, we also an-
alyzed other mechanisms that might explain the improved cardiac
function by StemBells, such as cardiac differentiation or an effect on in-
ﬂammatory cells.We did ﬁnd cardiomyocyte speciﬁcmarkers Connexin
43 and Troponin-T on the retraced stem cells, which may be indicative
for partial differentiation towards cardiomyocytes (Naaijkens et al.,
2012; Bai et al., 2010). However, the low number of retrieved stem
cells makes it highly unlikely that differentiation is a key mechanism.
Recently it was described that the ratio between the early and late
subtype of macrophages provides information about the course of in-
farct repair, especially as macrophages in the infarct area can release
substances that are of inﬂuence on the non-infarct healthycardiomyocytes (Ben-Mordechai et al., 2013; Cho et al., 2014). Therefore,
we analyzedmacrophage subpopulations within the infarct area by ED2,
the solemarker for rat type 2 anti-inﬂammatorymacrophages identiﬁed.
It was observed, that only very focally macrophages were present in the
non-infarct area in all groups. However, no difference between the
groups was found for the type 2 macrophages within the infarct area.
The fact that we found only a small difference in the number of re-
trieved stem cells ﬁveweeks after injectionmay indicate that themech-
anism behind improved heart function might be explained by
substances produced by StemBells exposed to ultrasound directly after
injection, but not by stem cells exposed to ultrasound. It has been dem-
onstrated that BM-MSCs produce and secrete awide range of cytokines,
chemokines and growth factors (extensively reviewed by Gnecchi et al.,
2008), and that hypoxia, e.g. the infarct area, increases this production
and secretion (Kinnaird et al., 2004; Gnecchi et al., 2008). According to
Gnecchi et al. (2008) some of the paracrine factors released may alter
the extracellular matrix, resulting in more favorable post-infarction re-
modeling and strengthening of the infarct scar (Gnecchi et al., 2008).
In addition, there is data suggesting that factors secreted by stem cells
may positively inﬂuence cardiac contractility. For example, insulin-like
growth factor (IGF-1) improved myocardial function in both normal
and infarcted adult rat hearts (Cittadini et al., 1996). Another suggestion
is the positive effect of secreted substances on bioenergetics in the post-
infarcted heart. Feygin et al. (2007) demonstrated in pigs that hearts in
theAMI groupdeveloped severe contractile dyskinesis in the infarct and
border zone, whereas BM-MSC transplantation signiﬁcantly improved
contractile performance. Interestingly, they also did not ﬁnd an effect
on infarct size. Because of low cell engraftment, the authors concluded
that the observed beneﬁcial effects were most likely attributable to
paracrine repair mechanisms (Feygin et al., 2007). It is also known
that an infarction results in a decrease in cardiomyocyte contractility
outside of the infarct area (Loennechen et al., 2002). It can be speculated
that the paracrine effects of StemBells exposed to ultrasound may posi-
tively affect cardiac contractility in the remote areas, therebypreventing
cardiac remodeling, and improving fractional shortening, although fur-
ther research in necessary to conﬁrm this.
14 L. Woudstra et al. / Stem Cell Research 17 (2016) 6–15The results described here demonstrate the potential of this novel
targeting technique. Although we focused on cardiac repair in AMI,
the StemBell technique bears the perspective to be applicable in a vari-
ety of diseases that may require regenerative cellular therapy.
In conclusion, the StemBell technique is a novel and feasible tech-
nique, able to improve cardiac function post-AMI in rats.
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